

**DRAFT AGENDA**

**Alliance for Clinical Trials in Oncology**

**May 14, 2020**

**Time: 11:30-1:00**

**Respiratory Committee**

Chair: Tom Stinchcombe, M.D.

Vice-Chairs: Dennis Wigle (Surgery)

Steven Schild (Radiation Oncology)

Stephen Graziano (Correlative Science)

**1. Committee overview, and protocol accrual – Chair and Xiaofei Wang (slides only available)**

**2. Intergroup trials**

**1. SWOG/NRG S1914: trial of immunotherapy followed by SBRT**

**followed by immunotherapy Apar Ganti**

**2. SWOG/Alliance S1827: PCI vs observation in ES-SCLC Jyoti Patel**

**3. E5142 Erin Bertino**

**4. NRG: SRS vs HA-WBRT SCLC brain metastases Steve Schild**

**5. ALK biomarker trial- Luda Bazhenova**

**2. NCI Lung-MAP Jyoti Patel**

Proposal: S1900X: A Phase II study of CB-839 and docetaxel in previously treated stagIV or recurrent squamous cell lung cancer patients harboring KEAP1 or NFE2L2 (NRF2) mutations Muhammad Furqan

**3. Mesothelioma–Robert Kratzke, Hedy Kindler, Arkadiusz Dudek**

**4. Stage IV Non-Small Cell Lung Cancer**

**1. A221504 - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta,**

Lyudmila Bazhenova

**DRAFT AGENDA**

**2. AFT-42:** Nivolumab for patients with compromised organ function – Becca

Heist, Phil Stella

**3. A082002** A Randomized Phase III Trial of Nivolumab plus Ipilimumab with or without SBRT for PD-L1-Negative Stage IV Non-Small Cell Lung Cancer Steven E. Schild and Christine Bestvina

**6. Stage III Non-Small Cell Lung Cancer**

**1. AFT-16:** Induction PDL-1 inhibition – Helen Ross, Jim Urbanic

**2. AFT-46:** Chemo-immunotherapy for operable stage III NSCLC Linda Martin, Jyoti Patel

**7. Early Stage Non-Small Cell Lung Cancer and Surgical Studies- Dennis Wigle**

**1. A151216- ALCHEMIST-** Personalized Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer: Geoff Oxnard

**2. A081105:** Erlotinib vs observation

**3. A081801: Adjuvant chemotherapy alone or in combination with pembrolizumab-** Jacob Sands

**4 A082001-** Colchicine to Prevent Recurrences Of Treated Early Cancers of the Thorax (C-PROTECT)

**8. Small Cell Lung Cancer**

**1. NRG 005:** ChemoRT +/- atezolizumab- Helen Ross

**2. AFT-52: ES-SCLC** A phase II study first line platinum-based therapy and durvalumab followed by maintenance durvalumab +/- olaparib +/- cediranib for extensive stage small cell lung cancer- Jacob Sands

**9. Metastatic disease** AFT-51 metastasectomy trial Linda Martin